Vancouver, Canada - October 2, 2018 - Aspect Biosystems, a leader in the field of 3D bioprinting and tissue engineering, is pleased to announce the appointment of Paul Hartley as its new Vice President of Engineering. Paul joins Aspect following management roles at Schneider Electric, GE, and PMC-Sierra. In this new role, Paul will manage all technical engineering aspects of the company’s technology development.
“Paul brings significant experience building and managing high performance and interdisciplinary technical teams for industrial commercial projects,” said Aspect CEO Tamer Mohamed. “Through our industry partnerships and global discovery ecosystem, our Lab-on-a-Printer™technology is currently being used to advance the development of breakthrough in vitro tissue models and therapeutic tissues. We are thrilled to have Paul join Aspect at a pivotal stage of growth as we focus on developing an industrial-grade biomanufacturing platform that builds on our core Lab-on-a-Printer™ technology to realize our cutting-edge tissue engineered products.”
“Aspect has generated strong validation and momentum around its core platform technology, and is uniquely positioned to capitalize on the strong potential of 3D bioprinting,” said Paul Hartley. “I look forward to building on this success, and working with the team to deliver a revolutionary 3D bioprinting manufacturing capacity, with the vision of enabling the creation of human tissues on demand.”
Paul brings more than 20 years of experience building technical teams and delivering leading-edge products to market. He joins Aspect from Schneider Electric, where he oversaw the specification and development of embedded, cloud, analytics, and mobile software for the company's utility-scale solar power inverter. He has also held leadership roles at General Electric and at the telecommunications semiconductor firm PMC-Sierra (now part of Microchip). Among his roles at PMC-Sierra, Paul led the development of ODM-ready hardware and software designs for VoIP ATA and broadband router. Paul holds a Bachelor's degree in Electrical Engineering from Simon Fraser University.
Aspect Biosystems is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal tissue development programs,Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used for impactful applications in therapeutic discovery and regenerative medicine. www.aspectbiosystems.com